apremilast / Generic mfg. - LARVOL DELTA

Single-Center Cross-Sectional Analysis of Patients with RA, SpA, and PsA: Data from the Prescription Database. (PubMed, J Pers Med) - "For RA, 34.2% of patients were difficult to treat (D2T) (98 pt), 54.8% (157 pt) were in monotherapy (tocilizumab-sarilumab-upadacitinib-filgotinib). Abatacept was the most prescribed treatment in RF and ACPA-positive patients and in those with ILD. The anti-IL-17A secukinumab was prescribed in 12% of SpA, of which 71% had enthesitis and dactylitis (14 pt). Ixekizumab was prescribed in 10.4% of PsA patients over 65 years with previous CV events, enthesitis, and dactylitis (21 pt). Apremilast was present in 71% of PsA with previous cancer...The cross-sectional analysis of prescriptions in patients with RA, SpA, and PsA demonstrates how the ITABIO recommendations can guide towards the correct appropriateness of prescription. RA and especially D2T-RA remains the disease with the greatest therapeutic failures, with the highest percentage of monotherapy (anti-IL-6 and Jak-i) and of discontinuation of MTX."

Journal • Ankylosing Spondylitis • Cardiovascular • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Interstitial Lung Disease • Metabolic Disorders • Ocular Inflammation • Oncology • Ophthalmology • Psoriatic Arthritis • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis • Uveitis • IL17A

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. (PubMed, Cochrane Database Syst Rev) - "Our review shows that, compared to placebo, the biologics infliximab, xeligekimab, bimekizumab, ixekizumab, and risankizumab were the most effective treatments for achieving PASI 90 in people with moderate-to-severe psoriasis, with high-certainty evidence for bimekizumab and moderate-certainty evidence for infliximab, xeligekimab, ixekizumab, and risankizumab. This network meta-analysis evidence is limited to induction therapy (outcomes measured from 8 to 24 weeks after randomisation), and is not sufficient for evaluating longer-term outcomes in this chronic disease. Moreover, we found low numbers of studies for some of the interventions, and the young age (mean 44.4 years) and high level of disease severity (PASI 20.5 at baseline) may not be typical of people seen in daily clinical practice. More randomised trials directly comparing active agents are needed, and these should include systematic subgroup analyses (sex, age, ethnicity, comorbidities, psoriatic arthritis)...."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Targeting Intracellular Pathways in Atopic Dermatitis with Small Molecule Therapeutics. (PubMed, Curr Issues Mol Biol) - "Although biologic agents such as dupilumab, tralokinumab, and lebrikizumab have revolutionized AD management, their high costs, injectable administration, and limited global accessibility highlight the need for alternative options...This review provides a comprehensive analysis of key agents including Janus kinase (JAK) inhibitors (upadacitinib, abrocitinib, baricitinib, ruxolitinib, delgocitinib), phosphodiesterase 4 (PDE4) inhibitors (crisaborole, difamilast, roflumilast, apremilast), as well as STAT6 degraders (KT621, NX3911), aryl hydrocarbon receptor modulators, histamine H4 receptor antagonists (adriforant, izuforant), and sphingosine-1-phosphate receptor modulators (etrasimod, BMS-986166). We summarize their mechanisms of action, pharmacological profiles, and pivotal clinical trial data, emphasizing their potential to address unmet therapeutic needs. Finally, we discuss safety concerns, long-term tolerability, and future directions for integrating small molecule..."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • STAT6

Generalized Pustular Psoriasis as a Systemic Inflammatory Disease: Experience With 38 Japanese Cases Over 15 Years at a Single Institution. (PubMed, Cureus) - "Pustular psoriasis is a rare subtype of psoriasis, classified into two broad forms: generalized and localized. In the present study, we retrospectively analyzed 41 cases of pustular psoriasis over a 15-year period at a single institution. There were 38 cases of generalized and three cases of localized pustular psoriasis. Among the 38 patients with generalized pustular psoriasis (GPP), 15 (39.5%) had a prior history of psoriasis, while the remaining patients developed GPP de novo. Eighteen patients were former or current smokers, and arthritis was observed in 12 patients. Four patients, including one with Turner syndrome, developed GPP in childhood. Episodes of generalized pustulation occurred once in seven patients, once in three patients, twice in three patients, and three times in one patient. The triggers of pustulation were upper respiratory infection (n=2), pregnancy (n=2), withdrawal of methotrexate (n=1), and paradoxical..."

Journal • Acute Respiratory Distress Syndrome • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Crohn's disease • Dermatology • Diabetes • Dyslipidemia • Gastroenterology • Genetic Disorders • Heart Failure • Hypertension • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • Nephrology • Psoriasis • Pulmonary Disease • Pustular Psoriasis • Renal Disease • Respiratory Diseases • Rheumatology • Turners Syndrome • S100A8 • S100A9

Ustekinumab in the Treatment of Intestinal Manifestations of Behcet's Disease (ACG 2025) - "Biopsy of the lesion showed vulvular neutrophilic dermatoses which prompted initiation of prednisone and cyclosporine. The patient developed hypertension on this regimen and transitioned to azathioprine...She was switched to adalimumab, colchicine and hydroxychloroquine by rheumatology...The medical team attempted methotrexate to prevent chronic glucocorticoid use, but the patient self-discontinued this medication due to gastrointestinal intolerance...She remains in clinical remission on Ustekinumab, apremilast, and sulfasalazine. A group of patients with intestinal BD experience disease refractory to mainstay therapy...This case demonstrates that, in patients with intestinal BD, Ustekinumab appears to be a potentially effective treatment. It represents a promising treatment option for intestinal BD, and further studies are needed."

Cardiovascular • Crohn's disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Hypertension • Immunology • Inflammation • Inflammatory Bowel Disease • Rare Diseases • Rheumatology

A systematic review and network meta-analysis comparing the efficacy and safety of deucravacitinib versus selected treatments for moderate to severe plaque psoriasis. (PubMed, Clin Rheumatol) - "Accumulating research, albeit of differing robustness, suggests that bimekizumab could potentially offer superior efficacy compared to other therapies in attaining both the PASI 75 and PASI 90 response thresholds in psoriasis treatment. Tildrakizumab appears to have achieved the highest proportion of participants reaching a static Physician's Global Assessment (sPGA) score of clear or almost clear (sPGA 0/1). Deucravacitinib has demonstrated moderate efficacy and tolerability; however, additional head-to-head comparative trials are warranted to substantiate its effects due to the paucity of existing studies. Key Points • The NMA of 66 RCTs reveals that infliximab, bimekizumab, and tildrakizumab are superior in achieving PASI 75, PASI 90, and sPGA 0/1, respectively, in moderate-to-severe plaque psoriasis, underscoring their therapeutic significance. • Deucravacitinib, an oral TYK2 inhibitor, outperforms placebo and apremilast in efficacy for moderate-to-severe plaque..."

Journal • Retrospective data • Dermatology • Immunology • Psoriasis • TYK2

Inhibition of Structural Damage Progression With Guselkumab in Participants With Active Psoriatic Arthritis: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study (ACG 2025) - "Here, we report Week 24(W24) results. APEX enrolled biologic naïve adults with active PsA (≥3 tender & ≥3 swollen joints; C-reactive protein ≥0.3mg/dL) and ≥2 erosive joints on radiographs of hands and feet despite previous non-biologic DMARDs, apremilast, or NSAIDs. BL characteristics were similar across groups. Mean duration of PsA(7.3yrs), PsA-modified vdH-S total(27.0) and erosion(13.5) scores, and tender(20.7) and swollen(11.9) joint counts indicated established, highly active joint disease. Primary and major secondary endpoints were met."

Clinical • P3 data • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP

Nasal Mucosal Manifestation of Behçet's Disease: A Case Report. (PubMed, Intern Med) - "These ulcers resolved along with the systemic symptoms following treatment with colchicine, apremilast, and prednisolone. Although there is no specific treatment strategy for nasal mucosal lesions in BD, standard systemic therapies may be effective. This case highlights nasal mucosal involvement as a rare but important manifestation of BD, emphasizing the importance of thorough evaluation and consideration of nasal symptoms for the diagnosis and treatment."

Journal • Rare Diseases

Use of Apremilast for the Treatment of Immune Checkpoint Inhibitor Psoriasis and Psoriatic Arthritis. (PubMed, Arthritis Care Res (Hoboken)) - "This study highlights the potential benefit of apremilast for the treatment of ICI-PsO, both de novo and PsO flare, with less of an apparent benefit for ICI-PsA. Thirty percent of patients in the whole group had to discontinue apremilast due to intolerance. Apremilast may be an attractive therapeutic option for either condition given that it is not immunosuppressive, but further prospective observational studies with larger patient numbers are needed."

Checkpoint inhibition • Clinical • Journal • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Autoimmune Hemolytic Anemia in a Patient with Generalized Pustular Psoriasis Treated with Brodalumab: A Case Report. (PubMed, J Nippon Med Sch) - "Herein, we report a case of generalized pustular psoriasis initially managed with etretinate, apremilast, and risankizumab in a Japanese man. Future studies should investigate whether AIHA accompanies pustular psoriasis or results from drug-induced AIHA secondary to brodalumab administration. Our findings suggest that the risk of AIHA in patients with psoriasis treated with brodalumab warrants careful consideration."

Journal • Anemia • Autoimmune Hemolytic Anemia • Dermatitis • Dermatology • Hematological Disorders • Immunology • Oncology • Psoriasis • Pustular Psoriasis • IL17A • TNFA

Effectiveness and Safety of Oral Apremilast in the Management of Oral Ulcers in Behcet's Disease: A Systematic Review. (PubMed, Indian Dermatol Online J) - "Apremilast has proved to be effective and safe in the management of oral ulcers in BD, indicating its use as a drug of choice. Further research with a longer follow-up period and an active comparator is required to determine its efficacy over long periods of administration."

Journal • Immunology • Inflammation • Rare Diseases

Comparative Risk of Infection and Prevalence of Combination Targeted Therapy in Psoriatic Arthritis. (PubMed, JAMA Dermatol) - "The most common combinations used different biologics with apremilast. This study found no significant difference between the incidence of serious bacterial and opportunistic infections requiring hospitalization compared with standard therapy, suggesting that combination targeted therapy may not be associated with significantly increased infection risk, but further larger studies are needed."

Journal • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A

Combining process chemistry and engineering to develop intensified and automated continuous manufacturing process: Application to apremilast synthesis (ACS-Fall 2025) - "This approach opens up the possibility of long continuous run times without requiring constant operator monitoring. This work demonstrates how combining process chemistry and engineering strengths can lead to effective development."

A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=21 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting | N=33 ➔ 21

Enrollment change • Enrollment closed • Dermatology • Immunology • Pediatrics • Psoriasis

Characteristics of Quality-of-Life High Responders With Plaque Psoriasis and High-Impact Site Involvement Treated With Apremilast: A Post Hoc Analysis of the EMBRACE Trial (EADV 2025) - No abstract available

HEOR • Retrospective data • Dermatology • Immunology • Psoriasis

Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus (clinicaltrials.gov) - P4 | N=64 | Recruiting | Sponsor: All India Institute of Medical Sciences, Bhubaneswar | Not yet recruiting ➔ Recruiting | Trial completion date: May 2025 ➔ Aug 2025 | Trial primary completion date: Jan 2025 ➔ Aug 2025

Enrollment open • Trial completion date • Trial primary completion date • Dermatology • Dermatopathology • Lichen Planus

Apremilast treatment is effective at treating both palms and soles in Japanese patients with moderate to severe palmoplantar pustulosis: Post-hoc analysis of a phase 3 study (EADV 2025) - No abstract available

Clinical • P3 data • Retrospective data • Immunology • Psoriasis

Apremilast Improves Patient-reported Pain Regardless of Sex and Age in Early Oligoarticular Psoriatic Arthritis: A Post-hoc Analysis From FOREMOST (EADV 2025) - No abstract available

Clinical • Retrospective data • Immunology • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Comparative Study of Two Classification Criteria Sets in Real Clinical Practice for Behçet's Disease. (PubMed, J Clin Med) - "Of the 32 patients classified as BD exclusively by ICBD, 7 were receiving anti-TNF therapy, and 2 were receiving apremilast. The ICBD criteria demonstrated higher sensitivity than the traditional ISG criteria in classifying BD, particularly in severe cases. Classifying these additional patients under ICBD facilitated the initiation of on-label biologic treatments, potentially enhancing BD management, especially for severe cases."

Journal • Rare Diseases • Rheumatology

A Patient With Granuloma Annulare and Lichen Planus Treated With Apremilast: A Case Report. (PubMed, Case Rep Med) - "Apremilast exhibits a favorable side-effect profile compared to conventional treatments and is a good treatment option with its ability to reduce cytokines implicated in the pathogenesis of GA and LP. Here, we report the case of a 55-year-old woman in whom apremilast treatment led to an almost complete resolution of her GA and LP."

Journal • Dermatology • Dermatopathology • Immunology • Inflammatory Arthritis • Lichen Planus • Oncology • Psoriasis • Psoriatic Arthritis • Rare Diseases • Rheumatology • Seronegative Spondyloarthropathies • CXCL8 • IFNG • IL12A • IL2 • IL5 • TNFA

emerging role of apremilast in hand dermatoses (EADV 2025) - No abstract available

Dermatology

Efficacy of Apremilast in Paediatric Patients With Plaque Psoriasis According to Disease Duration in the SPROUT Randomised Controlled Trial (EADV 2025) - No abstract available

Clinical • Dermatology • Immunology • Pediatrics • Psoriasis

A Case of Behçet's Disease Initially Presenting With Acute Dyspnea Due to Subglottitis. (PubMed, Cureus) - "Behçet's disease is an inflammatory disorder that can affect multiple areas of the body, including the mucous membranes of the mouth and genital region, eyes, skin, and joints. To our knowledge, acute dyspnea due to subglottitis has never been reported in patients with Behçet's disease."

Journal • Cough • Dermatology • Inflammation • Otorhinolaryngology • Pulmonary Disease • Rare Diseases • Respiratory Diseases

Targeted Impact: Apremilast Treatment Outcomes According to High-Impact Sites for Plaque Psoriasis with Limited Skin Involvement – A Post-Hoc Analysis from EMBRACE (EADV 2025) - No abstract available

Clinical • Retrospective data • Dermatology • Immunology • Psoriasis

Exploring apremilast in the treatment of lichen planus pemphigoides: a new remedy. (PubMed, Proc (Bayl Univ Med Cent)) - "This case report details the experience of a 67-year-old woman with a history of LPP, showing disease progression despite undergoing multiple conventional therapies. Faced with the inadequacy of traditional treatments, we achieved successful results by using apremilast as an effective intervention."

Journal • Dermatology • Dermatopathology • Immunology • Infectious Disease • Lichen Planus